Eli Lilly's Foundayo and Novo Nordisk's Wegovy Pill Clash in Oral GLP-1 Showdown
The competitive battle in the once-daily oral GLP-1 receptor agonist market has entered a critical phase of international commercial scaling. Following the U.S. Food and Drug Administration's (FDA) landmark approval of Eli Lilly’s once-daily oral small-molecule GLP-1 Foundayo (orforglipron) on April 1, 2026, Novo Nordisk has accelerated its own oral rollout to secure a dominant foothold in Europe.
Novo Nordisk Launches Oral Wegovy in Germany
On September 2, 2026, Novo Nordisk officially launched its oral Wegovy (semaglutide) weight-loss pill in Germany, marking the first country in the European Union where the oral formulation is commercially available. This launch represents a major tactical milestone as Novo Nordisk seeks to establish market share ahead of Lilly's planned European and UK commercial launch of Foundayo, which is expected in late 2026 or early 2027.
The German launch comes at a crucial time for Novo Nordisk. Analysts at Citi recently flagged a slowdown in new-to-brand prescription trends for Novo's injectable GLP-1 portfolio (Ozempic and Wegovy), noting that oral Wegovy remains the primary exception and growth driver for the franchise.
Market Dynamics and Financial Scale
The oral GLP-1 showdown is expected to reshape the broader metabolic landscape by offering a highly convenient, needle-free alternative to weekly injections.1
- Eli Lilly (NYSE: LLY): Backed by a $1.02T market cap, Lilly's TTM revenue reached $79.67B (+47.7% YoY) with an 83.4% gross margin. Lilly is leveraging its strong financial position and the commercial launch of Foundayo to challenge Novo's historical dominance in obesity care.
- Novo Nordisk (NYSE: NVO): Holding a $205.97B market cap, Novo Nordisk reported $329.43B TTM revenue (+2.1% YoY) with an 82.0% gross margin. Despite recent analyst downgrades and a 23.7% decline from its 52-week high, Novo's aggressive oral expansion in Europe is a key defense mechanism against Lilly's market share gains.
-
An instance of Needle-free oral formulations capture a vast metabolic patient cohort completely distinct from injectable therapy users. — The introduction of convenient, once-daily oral weight-loss options targets a massive patient segment that wants to bypass weekly injections. ↩︎